Synthetic data only. Never enter patient information; nothing is sent or stored. For clinicians. Not FDA cleared.For licensed clinicians. Educational demonstration on synthetic data. Never enter real patient identifiers or protected health information: everything runs in your browser and nothing is sent or stored. Clinical decision support only; not FDA cleared; physician review is required.
CPE-003 · synthetic case CKD-FX-014
Possible monoclonal protein-related kidney disease
Possible monoclonal protein-related kidney disease
Purpose: Use UACR/uPCR discrepancy and systemic features
Inputs the engine received
Patient
- Age
- 71 years
Context
- Sex for equation
- male
- UPCR UACR disproportion
- Yes
- Anemia present
- Yes
- Hypercalcemia present
- Yes
Laboratory
- eGFR selected
- 36 mL/min/1.73 m²
- UACR
- 65 mg/g
- UPCR
- 2400 mg/g
What the engine reports
Detected clinical pattern
Kidney Abnormality Detected — CKD Not Confirmed
A single abnormal result does not establish CKD. Persistence over at least three months and exclusion of acute or transient causes are needed.
- Chronicity: Chronicity unconfirmed
- CGA: Indicative G3bA2 (not a classification)
- Pattern: Possible non albumin proteinuria
- Pattern: Possible monoclonal protein related kidney disease
Clinical summary
A kidney abnormality was detected (eGFR 36 and UACR 65 mg/g), but chronicity is not established; CKD is not confirmed. Pattern flagged for adjudication: possible non albumin proteinuria. Priority: confirm persistence and exclude acute or transient causes.
Why this pattern was identified
- Estimated GFR. 36 mL/min/1.73 m² (externally reported), category G3b (30–44).
- Albuminuria. UACR 65 mg/g, category A2 (30–300 mg/g).
Calculations
- eGFR (externally reported)
- 36 mL/min/1.73 m²
Patterns for physician adjudication
Evidence shown, not scored: pattern weights are not clinically validated.
Possible monoclonal protein-related kidney pattern
Supporting
- anemia
- hypercalcemia
- non-albumin-predominant proteinuria
- older adult
Contradicting or missing
- No monoclonal protein testing available in the entered data
Recommended next steps
For physician consideration. Urgent review always comes first.
- 1Confirm persistence (repeat testing at ≥3 months) and evaluate acute or transient causes before labeling CKD.A single abnormal eGFR or UACR does not establish CKD.
- 2Clinician-directed serum and urine monoclonal protein evaluation and specialist review.Two or more monoclonal-protein clues are present.
- 3Specialist kidney-care referral per triggered criterion: Cause uncertain or hereditary concern.KDIGO 2024 referral criteria.
Why it matters
Isolated abnormal eGFR or UACR values are common and often transient. Labeling CKD early can misclassify patients, while missing persistent disease delays care. Confirmation at three months balances both.
Evidence and rule trace · 5 rules
DET-001Kidney abnormality detected
Inputs: eGFR 36 (<60) · UACR 65 mg/g (≥30)
kidney_abnormality_detected: determine chronicity and evaluate acute causes before confirming CKD
CHR-003Single abnormal result does not confirm CKD
Inputs: abnormality without dated evidence of ≥3 months
kidney_abnormality_unconfirmed: CKD is not confirmed
CAUSE-003Non-albumin predominant proteinuria pattern
Inputs: UPCR 2400 mg/g · UACR 65 mg/g · UPCR/UACR disproportion
possible_non_albumin_proteinuria: consider clinician-directed evaluation for tubular or monoclonal protein process
CAUSE-004Monoclonal protein-related kidney disease concern
Inputs: anemia · hypercalcemia · non-albumin-predominant proteinuria · older adult
possible_monoclonal_protein_related_kidney_disease: clinician-directed serum/urine monoclonal protein evaluation and specialist review
REF-001Nephrology referral triggers
Inputs: Cause uncertain or hereditary concern
Specialist kidney care referral indicated or to be considered per the triggered criterion
Evidence
- R1 · KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Disease: Improving Global Outcomes (KDIGO), 2024.
Physician adjudication required. Clinical decision support for physician review. Criteria-based status is not a probability. Findings require physician adjudication and correlation with the complete clinical context. Validation-only release: not for production clinical use.
Change the values
The same engine, starting from this case. Change any value and watch the pattern and the rule trace react.
Live eGFR and CGA map
eGFR (mL/min/1.73 m²)
36
externally reported
| GFR \ ALB | A1<30 | A230–300 | A3>300 |
|---|---|---|---|
| G1≥90 | |||
| G260–89 | |||
| G3a45–59 | |||
| G3b30–44 | ◌ | ||
| G415–29 | |||
| G5<15 |
Indicative cell G3bA2 only: CKD is not confirmed, so this is not a classification. Colors follow the KDIGO risk heat map: green low, yellow moderately increased, orange high, red very high.
Kidney functionAdd a prior result with dates to test chronicity
Switches the engine to the combined eGFRcr-cys equation.
Albuminuria
Chemistry
Kidney findings and red flags
Context
Transient albuminuria confounders
Creatinine may be unreliable
Complications (persistent)
Therapy
Documented history and special populations
This case also carries values that have no field here: eGFR_selected. They are included in the calculation until you clear the form.
More kidney cases
CKD-FX-001
Persistent moderately increased albuminuria with preserved GFR
Persistent moderately increased albuminuria with preserved GFR
CKD-FX-002
Persistent severely increased albuminuria with mildly decreased GFR
Persistent severely increased albuminuria with mildly decreased GFR
CKD-FX-003
Single reduced eGFR without chronicity
Single reduced eGFR without chronicity
CKD-FX-004
Acute creatinine rise before CKD staging
Acute creatinine rise before CKD staging
CKD-FX-005
Isolated suspected G3a requiring cystatin C confirmation support
Isolated suspected G3a requiring cystatin C confirmation support
CKD-FX-006
Combined eGFR reclassification support
Combined eGFR reclassification support
Try Biod in your practice
The Clinical Intelligence Layer — transforming fragmented clinical information into structured intelligence for clinician review and action.
